Ropes & Gray Advises Monte Rosa Therapeutics in Global Licensing Collaboration With Novartis
October 30, 2024
October 30, 2024
BOSTON, Massachusetts, Oct. 30 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Monte Rosa Therapeutics (Nasdaq: GLUE) in a global exclusive licensing agreement with Novartis to develop and commercialize a molecular glue degrader (MGD) drug for immune-related diseases. MGDs aim to selectively degrade and eliminate abnormal protein functions associated with some diseases that are hard to treat with existing medications. The agreement was announced on . . .
Ropes & Gray advised Monte Rosa Therapeutics (Nasdaq: GLUE) in a global exclusive licensing agreement with Novartis to develop and commercialize a molecular glue degrader (MGD) drug for immune-related diseases. MGDs aim to selectively degrade and eliminate abnormal protein functions associated with some diseases that are hard to treat with existing medications. The agreement was announced on . . .